All sponsors

Chengdu Zenitar Biomedical Technology Co., Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-32
RECRUITING7
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO38%

Delay Index: of 8 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Chengdu Zenitar Biomedical Technology Co., Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Flonoltinib 50mg
NCT06457425
P2Active, not recruitingMF,PMF,PPV-MF,PET-MF752025-11-26 (-5 mo)
Purinostat Mesylate 4 mg/m2
NCT06484829
P1/2RecruitingRelapsed or Refractory Multiple Myeloma (RRMM)1442026-02-01
A0/B0 group Purinostat Mesylate 11.2mg/m2
NCT06431243
P1/2RecruitingAdvanced Solid Tumor1322026-05-01
11.2 mg/m2 Purinostat Mesylate
NCT06485219
P2Active, not recruitingRelapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL)502026-06-30 (+7 mo)
PM 8.4 mg/m^2
NCT05563844
P2Active, not recruitingDiffuse Large B Cell Lymphoma,DLBCL742026-12-30 (+24 mo)
Flonoltinib 75mg
NCT07232290
P2RecruitingPolycythemia Vera (PV)602027-07-30
The high-dose group of ZL-82 tablets
NCT07193589
P2RecruitingAtopic Dermatitis1112027-12-30 (+12 mo)
Flonoltinib Maleate
NCT07443306
P2RecruitingMF642027-12-30
Flonoltinib 75mg
NCT07317700
P3RecruitingMF1052027-12-30
ZL-85FA tablets
NCT07339748
P1/2Not yet recruitingAdvanced Solid Tumor512028-06-30
FM-MF-02
NCT07750574
P2Not yet recruitingMyelofibrosis; Myelofibrosis Due to and Following Polycythemia Vera1052028-11
Purinostat Mesylate for Injection
NCT07011056
P3RecruitingRecurrent and Refractory Diffuse Large B-cell Lymphoma3902029-06-30